Degenerative Mitral Stenosis: From Pathophysiology to Challenging Interventional Treatment
Related Experiment Video
Updated: Feb 11, 2026

A Protocol to Acquire the Degenerative Tenocyte from Humans
Published on: June 9, 2018
Abstract:
Mitral stenosis (MS) is characterized by obstruction of left ventricular inflow as a result of narrowing of the mitral valve orifice. Although its prevalence has declined over the last decade, especially in developed countries, it remains an important cause of morbidity and mortality. The most often cause of MS worldwide is still postrheumatic mitral valve disease. However, in developed countries, degenerative or calcific changes cause MS in a siginificant proportion of patients. Although the range of treatment for mitral valve disease has grown over the years in parallel with transcatheter therapies for aortic valve disease, these improvements in mitral valve disease therapy have experienced slower development. This is mainly due to the more complex anatomy of the mitral valve and entire mitral apparatus, and the interplay of the mitral valve with the left ventricle which hinders the development of effective implantable mitral valve devices. This is especially the case with degenerative MS where percutaneous or surgical comissurotomy is rarely employed due to the presence of extensive annular calcification and at the base of leaflets, without associated commissural fusion. However, the last few years have witnessed innovations in transcatheter interventional procedures for degenerative MS which consequently hinted that in the future, transcatheter mitral valve replacement could be the treatment of choice for these patients.
Insights
Mitral stenosis (MS) obstructs blood flow due to mitral valve narrowing. Innovations in transcatheter procedures suggest future potential for degenerative MS treatment, offering new hope for patients.
Area of Science:
- Cardiology
- Interventional Cardiology
- Valvular Heart Disease
Background:
- Mitral stenosis (MS) obstructs left ventricular inflow, causing significant morbidity and mortality.
- While postrheumatic disease is the global cause, degenerative changes are increasingly prevalent in developed nations.
- Therapeutic advancements for mitral valve disease lag behind aortic valve disease due to complex anatomy and device challenges.
Purpose of the Study:
- To review the current landscape of mitral stenosis treatment.
- To highlight challenges in developing transcatheter mitral valve devices.
- To explore recent innovations in interventional procedures for degenerative mitral stenosis.
Main Methods:
- Review of current literature on mitral stenosis etiology and treatment.
- Analysis of challenges in transcatheter mitral valve interventions.
- Discussion of emerging transcatheter technologies for degenerative mitral stenosis.
Main Results:
- Degenerative mitral stenosis is common in developed countries, often lacking commissural fusion, making traditional interventions difficult.
- Transcatheter mitral valve replacement faces anatomical complexities, hindering device development.
- Recent innovations show promise for transcatheter interventions in degenerative mitral stenosis.
Conclusions:
- Transcatheter mitral valve replacement may become the preferred treatment for degenerative mitral stenosis.
- Continued innovation is crucial to overcome anatomical challenges for mitral valve interventions.
- Improved transcatheter therapies could significantly impact the management of mitral stenosis.
Related Concept Videos
Mitral Stenosis I: Introduction
Mitral Stenosis III: Medical Management
Mitral Stenosis IV: Nursing Management
Mitral Stenosis II: Clinical features and Diagnostic Tests
Nursing Interventions I: Taxonomy of Nursing Interventions
A nursing intervention is a treatment or action based on scientific concepts and knowledge from the nursing, behavioral, and physical sciences. Identifying and prioritizing nursing interventions based on the desired outcome...
Nursing Interventions II: Selecting and Classifying the Nursing Interventions

